Device Trial Radar · NCT04983862
Fluorescent Imaging of Nerves With Illuminare-1 During Surgery
Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Oct 4, 2021
Primary completion
Sep 9, 2025
Study completion Sep 9, 2025
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Illuminare Biotechnologies
- First posted
- Jul 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test the safety of using Illuminare-1 during standard surgery for prostate cancer. The study researchers will test increasing doses of Illuminare-1 to find the dose that makes the nerve structures fluoresce (light up) but causes few or mild side effects. When the researchers find this dose, it will be tested in new groups of study participants to see whether surgery performed using Illuminare-1 guidance is better than surgery performed without intraoperative guidance. The researchers will also do tests to study the way the body absorbs, distributes, and gets rid of Illuminare-1. This study is the first to test Illuminare-1 in people. Illuminare-1 has received Fast Track designation from the US FDA.
Conditions
- Prostate Adenocarcinoma
Interventions
Illuminare-1Drug
Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Dose levels of the agent will be administered starting at 0.25mg/kg, with increases in dose between cohorts of no more than 0.75 mg/kg until a maximum dose of 3.0mg/kg is reached, if needed. At the dose identified to have the acceptable NMR and no associated DLTs, Illuminare-1 will be studied in up to 20 additional patients at this dose to optimize the imaging protocol and provide additional safety data.
Karl Storz D-Light C photodynamic diagnostic (PDD)Device
The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.
Primary outcomes
What the sponsor says the trial is designed to measure.
- determine the safety of Illuminare-1Time frame: up to 45 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.